Canopus BioPharma (CBIA:PK) - Very Low Overhead for a Pharma
[?]
We often smirk when we hear about people complaining about the cost of healthcare because most people don’t understand the size of the research budgets of pharmaceutical companies. Canopus on the other hand has a very low budget. Most of the company’s research is outsourced and this keeps the costs low.
Tomorrow, we’ll be talking about Oltipraz, the company’s Phase II drug for a billion dollar indication.
Notice:
1800blogger.com, Inc. has been compensated $3,750 from Canopus BioPharma, Inc. to publicize the Canopus BioPharma, Inc. (CBIA:PK) story to investors. Please read the rest of our disclaimer which could be found by clicking on the link (disclaimer) at the top of any page on this blog.
